Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoTherapy ScienceFRA:30O -6.25%50 Piotroski F-Score is 4 as of Jul. 19, 2026, which is at its 10-year median of 4.00. GuruFocus rates FRA:30O with a GF Score™ of 50/100 and a GF Value™ of €0.08 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,334 Biotechnology companies, OncoTherapy Science ranks better than 74.06% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
OncoTherapy Science has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for OncoTherapy Science's Piotroski F-Score or its related term are showing as below:
FRA:30O'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 5
Current: 4
During the past 13 years, the highest Piotroski F-Score of OncoTherapy Science was 5. The lowest was 1. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
OncoTherapy Science Piotroski F-Score Related Terms
OncoTherapy Science Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:30O vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, OncoTherapy Science's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
OncoTherapy Science's current Net Income (TTM) was -4.96.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
OncoTherapy Science's return on assets of this year was -0.69242572. OncoTherapy Science's return on assets of last year was -0.94986857.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
OncoTherapy Science's gearing of this year was 0. OncoTherapy Science's gearing of last year was 0.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
OncoTherapy Science's current ratio of this year was 13.58252427. OncoTherapy Science's current ratio of last year was 3.37364798.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
OncoTherapy Science's number of shares in issue this year was 328.241. OncoTherapy Science's number of shares in issue last year was 261.144.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
OncoTherapy Science's gross margin of this year was 0.01724529. OncoTherapy Science's gross margin of last year was -0.016971.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
OncoTherapy Science's asset turnover of this year was 0.61473009. OncoTherapy Science's asset turnover of last year was 0.87401427.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
0
+
1
+
1
+
0
+
1
+
0
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
OncoTherapy Science has an F-score of 4 indicating the company's financial situation is typical for a stable company.
OncoTherapy Science (FRA:30O) has a Piotroski F-Score of 4 as of Jul. 19, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on OncoTherapy Science and its competitors. This is near median its historical median of 4.00. Over the past decade, OncoTherapy Science's Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, OncoTherapy Science ranks #346 out of 1334 companies in the Biotechnology industry, placing it in the top 25.9%.
Is OncoTherapy Science's Piotroski F-Score too high?
OncoTherapy Science's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. OncoTherapy Science's value of 4 is 33.3% above this industry median. Based on the distribution chart, OncoTherapy Science ranks #346 out of 1334 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #346 out of 1334 companies for Piotroski F-Score. This puts OncoTherapy Science in the upper half of its industry. The industry median Piotroski F-Score is 3.00. OncoTherapy Science's value of 4 is 33.3% above this benchmark. Historically, OncoTherapy Science's own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, OncoTherapy Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,334 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoTherapy Science's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on OncoTherapy Science and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoTherapy Science's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (FRA:30O) is currently considered Fairly Valued. The stock's GF Value™ is €0.08, compared to a current price of €0.08 — trading 3.1% above its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 33.3% above the Biotechnology industry median of 3.00. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For OncoTherapy Science (FRA:30O), the current Piotroski F-Score is 4 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (FRA:30O) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of €0.08 is trading 3.1% above its estimated GF Value™ of €0.08.
GuruFocus considers OncoTherapy Science to be Fairly Valued.
Key valuation signals for FRA:30O:
Piotroski F-Score: 4 (near median its 10-year median of 4.00)
GF Value™: €0.08 vs. price of €0.08 (3.1% above fair value)
Industry Position: 33.3% above the Biotechnology median (#346 of 1334)
No single metric tells the full story. See the FRA:30O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score
Get the complete analysis for FRA:30O
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:30O has been successfully added to your 
